Low Risk for IBD Relapse After Switch From IV to Subcutaneous Infliximab

(MedPage Today) -- Switching from intravenous to subcutaneous infliximab (Remicade) was safe and effective for patients with inflammatory bowel disease (IBD) in clinical remission, an observational study in France showed. Among 133 patients treated...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news